AS
NBIX icon

Altshuler Shaham’s Neurocrine Biosciences NBIX Stock Holding History

Altshuler Shaham’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-153
Closed -$20.2K – 346
2023
Q4 		$20.2K Sell
153
-55
-26% -$6.33K ﹤0.01% 195
2023
Q3 		$23.4K Buy
+208
New +$21.9K ﹤0.01% 209
2023
Q1 		– Sell
-500
Closed -$59.7K – 440
2022
Q4 		$59.7K Sell
500
-71
-12% -$8.32K ﹤0.01% 188
2022
Q3 		$59K Sell
571
-143
-20% -$14.5K ﹤0.01% 193
2022
Q2 		$70K Buy
714
+279
+64% +$25.8K ﹤0.01% 193
2022
Q1 		$41K Buy
+435
New +$36.9K ﹤0.01% 400
2020
Q4 		– Sell
-646
Closed -$62K – 442
2020
Q3 		$62K Buy
646
+179
+38% +$20.7K ﹤0.01% 208
2020
Q2 		$57K Buy
+467
New +$51.6K ﹤0.01% 189
2020
Q1 		– Sell
-262
Closed -$28K – 561
2019
Q4 		$28K Buy
262
+166
+173% +$17.4K ﹤0.01% 231
2019
Q3 		$9K Buy
+96
New +$8.97K ﹤0.01% 304

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Altshuler Shaham's NBIX Position: Q1 2024 in Review

Altshuler Shaham sold out of Neurocrine Biosciences (NBIX) in Q1 2024, closing a stake of 153 shares — an estimated $20.2K sold.

Altshuler Shaham first reported a position in NBIX in Q3 2019 and held it in 10 quarters. The position peaked at $70K in Q2 2022. 589 funds tracked by Wall St. Rank hold NBIX as of Q1 2024.

  • Altshuler Shaham reported no remaining Neurocrine Biosciences position as of Q1 2024 after selling out during the quarter.
  • Altshuler Shaham sold 153 Neurocrine Biosciences shares in Q1 2024, an estimated $20.2K.
  • Altshuler Shaham first reported a position in Neurocrine Biosciences in Q3 2019 and held it in 10 quarters.
  • Altshuler Shaham's Neurocrine Biosciences position peaked at $70K in Q2 2022.
  • 589 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2024.

Based on Altshuler Shaham's 13F filing for Q1 2024, filed 15 May 2024.